HAYWARD, Calif. The brand drugs division of Impax Labs has finished enrolling patients in a late-stage clinical trial of a drug for Parkinson’s disease, Impax announced Thursday.
Impax Pharmaceuticals said the APEX-PD trial is a multinational phase 3 trial of the drug IPX066 (carbidopa, levodopa), for subjects with early Parkinson’s.
“We are very pleased to have completed enrollment in APEX-PD, meeting an important milestone for IPX066 and for Impax Pharmaceuticals as we plan for potential product launch,” Impax Pharmaceuticals president Michael Nestor said. “We look forward to revealing the top-line results for this trial in early 2011.”